19 Real-world Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Talazoparib-Treated Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer and Germline BRCA Mutations
Optimizing Treatment Outcomes in HR+ Breast Cancer
An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.
Utilization of The Breast Cancer Index for HR+ Breast Cancer
Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.
Genomic Testing for HR+ Breast Cancer: Best Practices
Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.
NCCN Updates to Genomic Testing in HR+ Breast Cancer
A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.
Extended Adjuvant Therapy for HR+ Breast Cancer
The rationale for treating early-stage HR+ breast cancer with extended adjuvant therapy and factors that impact treatment selection.
2 Clarke Drive Cranbury, NJ 08512